[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-pregnancy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100649794","phase-1-dipyridamole-for-early-onset-preeclampsia-a-pilot-study-of-feasibility-pharmacokinetics-and-biological-effects-100649794",false,"NCT07738562","Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects","* Age ≥ 18 years\n* Singleton pregnancy\n* Established early-onset preeclampsia, with or without severe features, with gestational age from 26+0 to 33+6 weeks at enrollment, confirmed by best obstetric estimate\n* Hospitalization for maternal and\u002For fetal surveillance\n* Expectant management deemed appropriate by the treating clinical team at the time of enrollment\n* sFlt-1\u002FPlGF ratio ≥85 at screening\n* Confirmed viable fetus without a known or suspected major structural or chromosomal anomaly\n* Baseline platelet count ≥100,000\u002FµL\n* Ability to provide written informed consent\n\nExclusion Criteria\n\n* Immediate indication for delivery at time of screening, including uncontrolled severe hypertension, eclampsia, HELLP syndrome, or severe fetal compromise\n* Active maternal bleeding or clinically significant bleeding disorder\n* Therapeutic-dose anticoagulation (e.g., enoxaparin \\>1 mg\u002Fkg\u002Fday)\n* Known hypersensitivity or contraindication to dipyridamole\n* Multiple gestation\n* Known major fetal anomaly or chromosomal abnormality\n* Baseline thrombocytopenia, platelet count \\\u003C100,000\u002FµL\n* Hemodynamically significant maternal cardiac disease\n* Significant maternal comorbidity that, in the investigator's judgment, precludes safe participation\n* Inability to comply with study procedures","FEMALE","18 Years",{"count":18,"type":19},15,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","Early-onset preeclampsia (PE), defined as preeclampsia presenting before 34 weeks of gestation, is a severe placental disorder associated with significant maternal and perinatal morbidity. There is currently no disease-modifying treatment; management relies on close surveillance and delivery, frequently resulting in extreme prematurity.\n\nRecent laboratory research identified ferroptosis, a form of iron-dependent regulated cell death driven by lipid peroxidation, as a key mechanism of placental injury in early-onset preeclampsia. A high-throughput drug screen identified dipyridamole, an approved oral antiplatelet and vasodilatory agent, as a potent ferroptosis inhibitor in primary human trophoblast cultures (EC50 = 0.146 µM), acting through mechanisms independent of its known phosphodiesterase-inhibitory pharmacology. In preeclamptic placental explants, dipyridamole markedly reduced release of sFlt-1, a central mediator of the maternal syndrome. Dipyridamole carries an established pregnancy safety record supported by randomized trials and a Cochrane meta-analysis of antiplatelet agents in pregnancy.\n\nThis is a prospective, single-center, open-label pilot study using a sequential, fixed dose-escalation design. The study will enroll 15 hospitalized pregnant women with early-onset preeclampsia (gestational age 26+0 to 33+6 weeks) and an elevated sFlt-1\u002FPlGF ratio (≥85), for whom expectant management is clinically appropriate. Enrollment proceeds through a staged sentinel design with safety gates reviewed by an independent Safety Monitoring Committee. Participants receive oral dipyridamole added to standard clinical care, using a fixed dose-escalation protocol (75 mg twice daily on Day 1, escalating over 2-3 days to a target dose of 75 mg four times daily, 300 mg\u002Fday total). Standard obstetric care continues unchanged, determined entirely on clinical grounds, independent of study participation.\n\nThe primary objective is to evaluate the feasibility and clinical implementability of the dipyridamole treatment protocol within routine inpatient obstetric care. Secondary objectives include characterizing the pharmacokinetics of dipyridamole during pregnancy, assessing tolerability, and evaluating longitudinal circulating angiogenic biomarkers (sFlt-1 and PlGF). Exploratory objectives include assessment of placental markers of oxidative stress and ferroptosis-related pathways in tissue obtained at delivery.\n\nStudy drug is administered during the antepartum period only and discontinued before delivery. This pilot study is not designed to establish clinical efficacy, but to provide the pharmacokinetic, tolerability, and biological data required to design a subsequent randomized trial.",[26,27],"Preeclampsia (PE)","Hypertension ,Pregnancy",[29,30,31,32,33,34],"Preeclampsia treatment","preeclampsia management","treating mild preeclampsia","Early-onset preeclampsia","hypertensive pregnancy disease","preeclampsia disease-modifying therapy","NOT_YET_RECRUITING","2026-07-27",{"date":38,"type":39},"2026-07-31","ACTUAL",{"date":41,"type":19},"2026-09",{"date":43,"type":19},"2028-09",{"name":45,"class":46},"Hadassah Medical Organization","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":20,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100635309","impact-of-behavioural-modification-working-toolkit-among-women-with-gestational-diabetes-mellitus-and-hypertension-100635309","NCT07551011","Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension","Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged 15-49 years.\n* Gestational age between 16 and 20 weeks at enrolment.\n* Diagnosed with both gestational diabetes mellitus (GDM) and pregnancy-induced hypertension (PIH).\n* At least one prior antenatal visit at the study site.\n\nExclusion Criteria:\n\n* Pre-existing diabetes mellitus or chronic hypertension prior to pregnancy.\n* Pre-existing renal disease, thyroid disease, or major hematological disorders.\n* Multiple pregnancy (e.g., twins, triplets).\n* Severe psychiatric illness.","15 Years","49 Years",{"count":58,"type":19},220,[60],"NA","This trial aims to evaluate the effectiveness of a Behavioral Modification Working (BMW) Toolkit in improving glycemic control and blood pressure among pregnant women diagnosed with both GDM and PIH.",[63,27],"Gestational Diabetes Mellitus in Pregnancy",[65,66,67,68,69,70,71,72,73,74],"Gestational Diabetes Mellitus","Pregnancy Induced Hypertension","Maternal health","Childbirth","Risk Factors","intervention","BMW Toolkit","Dietary habits","Physical activity","sleep pattern","RECRUITING","2026-07-09",{"date":78,"type":39},"2026-07-13",{"date":80,"type":39},"2026-04-21",{"date":82,"type":19},"2027-01-15",{"name":84,"class":46},"University of the Punjab",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":20,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100602762","remote-physical-activity-intervention-for-high-blood-pressure-postpartum-100602762","NCT07127731","REmote Physical ACtivity Intervention for High Blood Pressure Postpartum","REACH BP: REmote Physical ACtivity Intervention for High Blood Pressure Postpartum","REACH BP","Inclusion Criteria:\n\n* Delivery of a live birth at Northwestern Medicine 6-12 weeks prior\n* Systolic blood pressure 120-139 or diastolic blood pressure 80-89 during the first 20 weeks of gestation\n* Low self-reported physical activity levels\n* Able to access the internet at least weekly\n* Have patient portal account or willing to set one up\n* Willing to wear a FitBit\n* Spoken and written English or Spanish language fluency\n\nExclusion Criteria:\n\n* Medical contraindications to participating in a structured physical activity program\n* Currently participating in a structured physical activity or weight loss program\n* Hypertensive disorder of pregnancy (e.g., preeclampsia, gestational hypertension, eclampsia)",{"count":95,"type":19},60,[60],"The purpose of this intervention is to help new mothers who had elevated blood pressure during pregnancy become more physically active after birth. The investigators will connect data from FitBits to the electronic health record. Women will then get weekly messages with feedback and goals to help them stay active. The investigators will test if the intervention improves step counts and blood pressure after pregnancy. The investigators will also test if the intervention is feasible and enjoyed by postpartum women.",[99,27,100],"Hypertension (HTN)","Physical Activity",[102,103,104,105],"hypertension","pregnancy","postpartum","physical activity","2026-03-19",{"date":108,"type":39},"2026-03-23",{"date":110,"type":19},"2027-04",{"date":112,"type":19},"2028-04",{"name":114,"class":46},"Northwestern University"]